Safety in second place?

The safety of newly marketed drugs is always provisional, based on the relatively limited population the drugs are used in prior to marketing. The number of subjects who take a drug in clinical trials is large enough to detect efficacy, but too small to detect rare, but serious, adverse events.…

Paracetamol: Recall bias and media bias

Just a short note. A couple of years ago there was a great deal of fuss about paracetamol and a possible link with asthma in children [Lancet]. The study reported on was a large retrospective study (205 487 children) involving surveying parents about their children's previous paracetamol use and symptoms…

Fly posting

I'm presenting a couple of posters at the International Society of Pharmacovigilance Conference this week. One is concerned with possible neuropsychiatric reactions to varenicline, and the other uses the DoTS ADR classification system to analyse reports of angioedema with angiotensin-II receptor antagonists. Further details at the links in the text.
1 2 3 24